BioMarin Just Bet $275M That You'll Swallow a Pill Instead of Taking a Shot

Why an Oral Drug Changes Everything

In rare disease, how you deliver a drug matters almost as much as what the drug does. Strensiq requires regular subcutaneous injections, which creates a real burden for patients and families. It's the biotech equivalent of only being able to listen to music on a record player: it gets the job done, but the world has moved on.

ALE1 isn't an enzyme replacement at all. Instead of flooding the body with the missing enzyme from outside, it works upstream by reducing the PPi that accumulates when that enzyme is deficient. In preclinical studies, oral dosing showed consistent PPi reduction across multiple animal models. That's a fundamentally different approach, and it comes in a much friendlier package.

For patients who might need lifelong therapy, the convenience gap between a pill and a needle is enormous. It could also expand the treatable population. Many adults with milder HPP may never start injectable therapy because the burden feels disproportionate to their symptoms. A pill could change that math entirely.

Early Days, Real Risk

Let's be clear about where ALE1 actually stands: it's in a Phase 1/2a clinical trial. That's early. A healthy volunteer study started in October 2025, and patient dosing was expected in the first half of 2026, with initial HPP patient data anticipated in the second half of this year.

No efficacy data in HPP patients has been disclosed yet. BioMarin is paying $275 million upfront for a drug that hasn't proven it works in the people who need it. That's a meaningful bet, even for a company with BioMarin's balance sheet.

The deal's structure reflects that risk. The $215 million in milestone payments act as a safety net: BioMarin only pays the full $490 million if ALE1 clears specific development and regulatory hurdles. According to Reuters, the upfront price represents a 41% premium to RTW Biotech Opportunities' carrying value of its Alesta investment as of July 31. That's above book value but not outrageous for a clinical-stage rare disease asset with first-in-class potential. BioMarin also flagged that the deal will be modestly dilutive to 2026 financials (excluding the upfront payment), signaling this is a long-term pipeline play, not a near-term earnings booster.

BioMarin's Rare Disease Shopping Spree

This isn't BioMarin's first trip to the acquisition aisle recently. The company bought Inozyme Pharma for roughly $270 million, picking up INZ-701 (now BMN 401), a late-stage enzyme replacement therapy for ENPP1 deficiency. It also announced a deal to acquire Amicus Therapeutics, which would bring in Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease.

A pattern is emerging. BioMarin is systematically building a broader rare disease empire, with particular emphasis on skeletal and metabolic conditions. The Alesta deal adds something the other acquisitions don't: an oral small molecule. BioMarin already has BMN 349, an oral therapeutic in development for alpha-1 antitrypsin deficiency-associated liver disease, but ALE1 would be a second oral program in a portfolio still dominated by biologics and gene therapies.

The strategic message is clear: BioMarin wants to own rare disease across modalities, not just injectable biologics.

The Race Is Already On

BioMarin won't be alone in this space for long. Recursion acquired full rights to an ENPP1 inhibitor program (REV102), with Phase 1 expected in the second half of 2026. Like ALE1, it's an oral small molecule targeting HPP.

So the oral HPP race has two horses, and both are still warming up. ALE1 has a slight head start, having already entered the clinic, while REV102 is still in the starting gate. But clinical development is a long race; being first to dose doesn't guarantee being first to market.

The broader competitive landscape for oral small molecules in rare metabolic bone diseases is surprisingly sparse. Most programs in adjacent conditions (like hypoparathyroidism) remain preclinical or rely on injectable biologics. HPP is the primary battleground, and there are really only two serious contenders right now.

The Bottom Line

BioMarin paid a disciplined price for a high-upside, high-risk asset. If ALE1 works in patients, it could redefine how HPP is treated and unlock a patient population that currently goes undertreated because injections feel like too much. If it doesn't work, BioMarin loses $275 million but avoids paying the remaining $215 million in milestones.

The real test comes later this year, when initial HPP patient data is expected. That readout will determine whether BioMarin bought a future blockbuster or an expensive lottery ticket. For HPP patients stuck with needles, the answer matters a lot more than the stock price.

An LSD Pill Just Aced a Late-Stage Anxiety Trial. Yes, Really.

An LSD-derived pill just posted the first positive Phase 3 result for any psychedelic-derived anxiety therapy, beating Wall Street expectations with a 5.4-point improvement over placebo. With a second pivotal trial reading out in weeks, the most stigmatized molecule in psychiatry is suddenly knocking on the FDA's door.